Navigation Links
3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB-2640 in Patients with Advanced Solid Tumors

MENLO PARK, Calif., Dec. 4, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the recent initiation of a Phase 1 clinical study of TVB-2640 in patients with advanced solid tumors.  TVB-2640 is an oral, proprietary fatty acid synthase (FASN) inhibitor being evaluated for the treatment of solid tumors.  FASN is an enzyme responsible for the synthesis of palmitic acid and has a key role in tumor metabolism, lipid signaling and tumor cell survival.


"For tumors to grow, cancer cells need to process more fuel than normal cells.  The ability to interfere in tumor cell metabolism is an extremely compelling avenue for oncology drug development," said Jeffrey Infante, M.D., Sarah Cannon Research Institute in Nashville, TN and lead investigator for the 3-V clinical trial.  "TVB-2640 is the first inhibitor of FASN to enter the clinic. Our center is excited to be leading the Phase 1 clinical study for this emerging and promising anti-cancer therapy."

The Phase 1 open-label, dose-escalation trial will enroll patients with advanced solid tumors whose cancer has become refractory to standard therapy, and for whom no useful treatment exists.  Patients will receive TVB-2640 once daily for 21 days.  The primary endpoint for the Phase 1 study is the identification of any dose-limiting toxicities and the establishment of a maximum-tolerated dose (MTD) for oral TVB-2640.  Secondary and exploratory endpoints include safety, pharmacokinetics, and initial signs of efficacy and evidence of FASN biomarker activity.

"With the initiation of this Phase 1 clinical trial, we look forward to testing our hypothesis that blocking FASN could provide a significant benefit in patients with solid tumors," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  Data from this trial will provide further information on the safety profile, dosing and selection of cancer types in anticipation of future studies for TVB-2640."

FASN over-expression is associated with aggressive disease and poor prognosis in a number of cancers. In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers. FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner and single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts. In addition, 3-V has demonstrated potential synergy of its FASN inhibitors with cytotoxic agents.  

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company discovering and developing therapeutics that modulate key pathways in oncology and infectious disease. In oncology, the company's lead candidate is a fatty acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and induces tumor cell apoptosis. 3-V's antiviral therapeutics block host-pathogen interactions, resulting in robust and broad-spectrum antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The
3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward.  The company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit

Contact Information

Merdad Parsey, M.D., Ph.D.
Chief Executive Officer

Media Inquiries

BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
Michelle Corral

SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
2. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
3. ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
4. 3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
5. Lilly Statement on Contribution to Indiana Biosciences Research Institute
6. Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
7. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
10. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
11. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Figure 1, a free mobile-first network ... cases, has launched a new completely redesigned web version ... allows radiologists, who work primarily on a desktop, to ... with its radiologist user base, Figure 1 is hosting ... North America (RSNA) Annual Meeting. ...
(Date:11/24/2015)... NEW YORK , Nov. 24, 2015 iRhythm ... on advancing cardiac care, today announced that it will participate in ... Palace Hotel in New York, NY . ... to present on Tuesday December 1, 2015 at 8:50am ET. ... Inc. . --> . ...
(Date:11/24/2015)... , Nov. 24, 2015 Teledyne DALSA ... X-Ray image sensing technology, will introduce its CMOS X-Ray ... Exhibition , November 29 to December 3, at McCormick Place ... dynamic detectors for diagnostic and interventional imaging will be on ... Xineos family of advanced CMOS X-Ray detectors is the ...
Breaking Medicine Technology:
(Date:11/24/2015)... SAN FRANCISCO, CA (PRWEB) , ... November 24, ... ... launched half-cup sizes, has launched their Black Friday sale a week early, offering ... ThirdLove continues to transform the intimate apparel industry through both mobile fit technology ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... ... are national leaders when it comes to several aspects of orthopedic care. They ... joint replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review ...
(Date:11/24/2015)... California (PRWEB) , ... November 24, 2015 , ... ... Energy's LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy ... controlled low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... United States to support their local poison centers through donations on Tuesday, Dec. ... calls it “a day that inspires people to collaborate in improving their ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
Breaking Medicine News(10 mins):